← Leaderboards
Steven Foung
Stanford University
$16,127,140
Attributed
$21,503,052
Total exposure
18
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$37,255,048 · 20
By mechanism
U19$24,167,280 · 13
R01$11,641,968 · 4
R41$600,000 · 1
R21$439,550 · 1
R56$406,250 · 1
Top collaborators
- Roy A Mariuzza7 shared
- Brian G. Pierce7 shared
- Alexander Andrianov5 shared
- Thomas R Fuerst5 shared
- Frederick Wayne Holtsberg1 shared
- Kelly Lyn Warfield1 shared
Most similar at Stanford University
Same institution · by research overlap
- Peter R Parham$35,417,272
- Peter Sarnow$27,278,753
- Mark A Kay$46,920,488
- Harry Bernard Greenberg$91,083,131
- Jianghong Rao$21,022,312
Others in their field
Top investigators on “Hepatitis C Virus”
- Constance Ann Benson · University Of California, San Diego$150,079,712
- Sharon A Nachman · Johns Hopkins University$91,575,784
- Peter B. Gilbert · Fred Hutchinson Cancer Center$77,122,577
- Robert Turner Schooley · University Of Colorado Denver$45,719,253
- Charles R Rinaldo · University Of Pittsburgh At Pittsburgh$44,694,148
- Charles M. Rice · Rockefeller University$42,549,577
Research focus
Hepatitis C VirusNeutralizing AntibodyB-LymphocytesHepatitis CResponseVirusAntibodiesViralImmunityVaccine DesignPreventProgramsEpitopesDesignImmunogenicT-LymphocyteVaccinesHuman Monoclonal AntibodiesGenotypeGlycoproteinsImmunogenicityAntigensReceptorStructure
Grant awards (56)
A vaccine design to induce protective B and T cell immunity against hepatitis C virus$2,268,699
U19 · FY2025 · AI · contact PI
Project-003$620,879
U19 · FY2025 · AI · contact PI
Project-004$288,164
U19 · FY2025 · AI · contact PI
Project-002$212,836
U19 · FY2025 · AI · contact PI
Core-001$170,996
U19 · FY2025 · AI · contact PI
Admin-Core-001$170,815
U19 · FY2025 · AI · contact PI
A vaccine design to induce protective B and T cell immunity against hepatitis C virus$2,272,798
U19 · FY2024 · AI · contact PI
Structure-guided vaccine design of HCV E1E2 to induce broadly neutralizing antibodies (bNAbs)$1,074,915
U19 · FY2024 · AI · contact PI
Administrative Core$141,215
U19 · FY2024 · AI · contact PI
A vaccine design to induce protective B and T cell immunity against hepatitis C virus$2,479,615
U19 · FY2023 · AI · contact PI
Structure-guided vaccine design of HCV E1E2 to induce broadly neutralizing antibodies (bNAbs)$965,967
U19 · FY2023 · AI · contact PI
Administrative Core$297,178
U19 · FY2023 · AI · contact PI
A vaccine design to induce protective B and T cell immunity against hepatitis C virus$2,498,468
U19 · FY2022 · AI · contact PI
Structure-guided vaccine design of HCV E1E2 to induce broadly neutralizing antibodies (bNAbs)$387,482
U19 · FY2022 · AI · contact PI
Administrative Core$308,104
U19 · FY2022 · AI · contact PI
A vaccine design to induce protective B and T cell immunity against hepatitis C virus$2,377,023
U19 · FY2021 · AI · contact PI
Structure-Based Vaccine Design for Hepatits C Virus$1,120,994
R01 · FY2021 · AI
Structure-guided vaccine design of HCV E1E2 to induce broadly neutralizing antibodies (bNAbs)$703,062
U19 · FY2021 · AI · contact PI
Administrative Core$208,047
U19 · FY2021 · AI · contact PI
Structure-Based Vaccine Design for Hepatits C Virus$1,128,779
R01 · FY2020 · AI
Profiling the protective B cell response to HCV$668,744
U19 · FY2020 · AI · contact PI
Humoral immunity against hepatitis C in protected subjects$579,812
U19 · FY2020 · AI · contact PI
Admin Core$44,607
U19 · FY2020 · AI · contact PI
Structure-Based Vaccine Design for Hepatits C Virus$1,136,335
R01 · FY2019 · AI
Profiling the protective B cell response to HCV$966,661
U19 · FY2019 · AI · contact PI
Humoral immunity against hepatitis C in protected subjects$706,054
U19 · FY2019 · AI · contact PI
Admin Core$44,607
U19 · FY2019 · AI · contact PI
Structure-Based Vaccine Design for Hepatits C Virus$1,142,860
R01 · FY2018 · AI
Profiling the protective B cell response to HCV$769,796
U19 · FY2018 · AI · contact PI
Humoral immunity against hepatitis C in protected subjects$511,706
U19 · FY2018 · AI · contact PI
Admin Core$42,089
U19 · FY2018 · AI · contact PI
Structure-Based Vaccine Design for Hepatits C Virus$1,449,630
R01 · FY2017 · AI
Profiling the protective B cell response to HCV$752,246
U19 · FY2017 · AI · contact PI
Humoral immunity against hepatitis C in protected subjects$470,243
U19 · FY2017 · AI · contact PI
Structure-based HCV vaccine design$193,150
R21 · FY2017 · AI · contact PI
Admin Core$46,591
U19 · FY2017 · AI · contact PI
Profiling the protective B cell response to HCV$697,946
U19 · FY2016 · AI · contact PI
Humoral immunity against hepatitis C in protected subjects$329,719
U19 · FY2016 · AI · contact PI
Structure-based HCV vaccine design$246,400
R21 · FY2016 · AI · contact PI
Admin Core$90,196
U19 · FY2016 · AI · contact PI
Immunotherapeutics to prevent HCV reinfection$300,000
R41 · FY2014 · AI
Immunotherapeutics to prevent HCV reinfection$300,000
R41 · FY2013 · AI
B Cell Immunity to Hepatitis C Virus$406,250
R56 · FY2009 · AI · contact PI
Neutralizing Antibodies to Hepatitis C$589,711
R01 · FY2008 · HL · contact PI
Neutralizing Antibodies to Hepatitis C$573,554
R01 · FY2007 · HL · contact PI
Neutralizing Antibodies to Hepatitis C$557,869
R01 · FY2006 · HL · contact PI
Neutralizing Antibodies to Hepatitis C$555,699
R01 · FY2005 · HL
Humoral Immune Response in Hepatitis C$341,260
R01 · FY2005 · AI
Neutralizing Antibodies to Hepatitis C$562,782
R01 · FY2004 · HL
Humoral Immune Response in Hepatitis C$332,020
R01 · FY2004 · AI
Humoral Immune Response in Hepatitis C$323,050
R01 · FY2003 · AI
IMMUNOLOGIC RESPONSE OF INTRAVENOUS DRUG USERS TO HTLV$389,641
R01 · FY2002 · DA
Humoral Immune Response in Hepatitis C$314,337
R01 · FY2002 · AI
IMMUNOLOGIC RESPONSE OF INTRAVENOUS DRUG USERS TO HTLV$379,894
R01 · FY2001 · DA
Humoral Immune Response in Hepatitis C$302,623
R01 · FY2001 · AI
IMMUNOLOGIC RESPONSE OF INTRAVENOUS DRUG USERS TO HTLV$440,930
R01 · FY2000 · DA